A 52-year-old man with advanced pancreatic cancer is on chronic opioid therapy for pain management. He develops severe constipation unresponsive to standard laxatives. Which is the most common adverse effect limiting long-term opioid use in cancer patients?

Explanation

## Most Common Opioid Adverse Effect in Chronic Use **Key Point:** Constipation is the single most common and most troublesome adverse effect of chronic opioid therapy, affecting 40–90% of patients on long-term opioids. ### Why Constipation Dominates Opioids cause constipation through multiple mechanisms: 1. **Mu receptor activation** in the enteric nervous system → decreased acetylcholine release 2. **Reduced GI motility** → increased water absorption → hard stools 3. **Increased anal sphincter tone** → difficulty defecation 4. **Tolerance does NOT develop** to the constipating effect (unlike analgesia, respiratory depression) **Clinical Pearl:** Unlike tolerance to analgesia and respiratory depression, tolerance to opioid-induced constipation does NOT occur. This makes it a persistent problem throughout therapy. ### Comparison with Other Adverse Effects | Adverse Effect | Frequency | Tolerance Develops? | Clinical Significance | |---|---|---|---| | **Constipation** | 40–90% | **No** | Most common, limits compliance | | Respiratory depression | 1–5% (chronic) | Yes | Dose-limiting in acute use | | Psychological dependence | Variable | — | Risk with misuse; less common in cancer | | Urinary retention | 5–15% | Yes | Uncommon; more with spinal opioids | **High-Yield:** Constipation is the **only opioid adverse effect for which tolerance does NOT develop**. This is why prophylactic bowel regimens (stool softeners + osmotic laxatives ± methylnaltrexone) are standard in cancer pain management. ### Management Strategy **Mnemonic: BOWEL** — **B**isacodyl, **O**smotic agents (lactulose, polyethylene glycol), **W**ater intake, **E**xercise, **L**axatives (prophylactic) For refractory cases: methylnaltrexone (peripheral mu antagonist) or naloxegol (PEG-naloxone) are opioid-sparing options. **Warning:** Do NOT assume tolerance will develop to constipation — it will not. Prophylaxis is mandatory from day 1 of opioid initiation.